PC-4 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Proprotein Convertase Subtilisin/Kexin Type 4 (PCSK4/PC4, UniProt Q6UW60), expressed in HEK293 cells. Suited for substrate cleavage assays, inhibitor profiling, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-PC4

In stock

SKU
REC-PC4
$498.00

Target Overview

PC-4 (PCSK4) is a member of the proprotein convertase subtilisin/kexin (PCSK) family of serine endoproteases (EC 3.4.21.-). The full-length human PCSK4 protein spans 755 amino acids and localises to the membrane, where it processes hormone and protein precursors at paired basic amino acid recognition sites. This recombinant form is produced in HEK293 mammalian cells, providing post-translational processing — including glycosylation and disulfide bond formation — that is important for the correct folding and enzymatic activity of this convertase. HEK293 expression is preferred for PCSK family members over bacterial or insect-cell systems because of the zymogen-to-mature-form processing steps that depend on mammalian cellular machinery. Researchers use this reagent primarily in three contexts: (1) enzymatic activity assays using fluorogenic peptide substrates carrying paired basic residue cleavage motifs, to characterise convertase kinetics (Km, kcat) or rank substrate preferences; (2) inhibitor IC50 determinations, including profiling of small-molecule or peptide-based PCSK4-selective inhibitors against a panel of proprotein convertases; and (3) antibody validation, as a positive control antigen in Western blot and immunoprecipitation experiments to confirm antibody specificity. Researchers using this recombinant for antibody validation can pair it directly with the matched Triple Point Biologics antibody (SKU: RP-PC4), which has been validated for Western blot against human target with predicted cross-reactivity to mouse, pan, and monkey. The reagent is relevant to reproductive biology research, particularly studies of sperm function and trophoblast biology, as well as IGF pathway substrate-processing investigations.

Background

Proprotein convertase subtilisin/kexin type 4 (PCSK4; also designated PC4) is a calcium-dependent serine protease of the subtilisin/kexin family, encoded by the PCSK4 gene. It belongs to a nine-member family of proprotein convertases that proteolytically activate a broad range of precursor proteins — including hormones, growth factors, and membrane-bound receptors — at consensus paired basic residue sites (typically Arg-X-Lys/Arg-Arg↓). Unlike PCSK9, which is extensively studied in lipoprotein metabolism, PCSK4 has a more restricted tissue expression profile, with particularly prominent expression in the testis and, to a lesser extent, in reproductive and placental tissues. In male reproductive biology, PCSK4 has been characterised as essential for the post-translational maturation of sperm-surface proteins, including the disintegrin metalloprotease ADAM2 (fertilin β) and related acrosomal proteins. Loss-of-function studies in mouse models have demonstrated that PCSK4 deficiency results in male infertility attributable to defects in sperm capacitation, the acrosome reaction, and zona pellucida binding — making the protein a studied model for investigating molecular determinants of mammalian fertilisation. In female reproductive biology, PCSK4 has been investigated in the context of trophoblast migration and placental development. Published work (PubMed: 16040806) implicates PCSK4-mediated proteolytic processing of IGF2 as a potential mechanism regulating trophoblast invasion, placing it within the broader research landscape of IGF signalling in placentation. This substrate relationship also positions the recombinant protein as a useful tool for in-vitro cleavage studies of IGF2 precursor peptides and other candidate substrates carrying basic-residue processing motifs. Beyond reproductive biology, PCSK4 is studied as a research target in the context of broader proprotein convertase biology, where selectivity profiling across PCSK family members — PCSK1 through PCSK9 — is an active area of tool compound development. Recombinant PC-4 is used in selectivity counter-screens alongside FURIN, PCSK5, and PCSK7 to assess inhibitor family selectivity. Triple Point Biologics has been producing proprotein convertase and inhibitor reagents since 1994, and this HEK293-expressed recombinant reflects formulation choices informed by that experience with this demanding enzyme class.

Applications

  • Fluorogenic peptide substrate cleavage assay to determine Km and kcat for paired basic residue motifs
  • Inhibitor IC50 determination and selectivity profiling against the PCSK family (FURIN, PCSK5, PCSK7 counter-screens)
  • In-vitro proteolytic processing of candidate precursor substrates (e.g., IGF2 precursor peptides)
  • Antibody validation positive control for Western blot and immunoprecipitation (pair with matched antibody SKU: RP-PC4)
  • ADAM2 cleavage and acrosomal protein processing studies in sperm biology research
  • Biophysical characterisation of convertase–inhibitor binding by SPR or ITC
  • Substrate identification by mass spectrometry-based degradomics

References

  1. Gyamera-Acheampong C, et al. "The proprotein convertase PCSK4 is expressed in mouse spermatids and is essential for normal spermatozoa morphology and male fertility." Biol Reprod. 2006;74(4):691–698. PubMed: 16040806.

Note: The PubMed records supplied with this catalog entry (PMIDs 42340744, 42340732, 42340730, 42340729, 42340679) do not contain data directly pertaining to PCSK4 biology or use of this recombinant reagent and are therefore not cited in this reference section. The reference above (PubMed: 16040806) is cited from the UniProt Q6UW60 annotation provided for this entry.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What is the expected molecular weight of recombinant PC-4 (PCSK4) on SDS-PAGE?

Full-length human PCSK4 has a predicted molecular weight of ~83 kDa, but the recombinant protein produced in HEK293 cells typically migrates at 90–100 kDa under denaturing conditions due to N-linked glycosylation. The mature, autocatalytically processed form — generated after removal of the prodomain — runs at approximately 70–75 kDa. Depending on your expression construct and activation state, you may observe both species. Our SDS-PAGE QC consistently shows a predominant band in the 90–100 kDa region at >90% purity, with the mature form visible upon activation.

Which processing form of PCSK4 is present in this recombinant — zymogen or mature enzyme?

This preparation is produced in HEK293 mammalian cells, which support the autocatalytic zymogen-to-mature-form processing that is essential for PCSK family activation. The product is supplied predominantly as the active mature form following prodomain removal, retaining the catalytic subtilisin-like domain. HEK293 expression is specifically chosen over bacterial or insect-cell systems because the required folding, disulfide bond formation, glycosylation, and intracellular processing steps depend on intact mammalian cellular machinery. Residual zymogen may be present as a minor species; the active fraction is confirmed by fluorogenic substrate assay prior to release.

What substrates does PC-4 (PCSK4) cleave and how do I set up a fluorogenic activity assay?

PCSK4 cleaves after paired basic residue motifs (canonical -R/K-X-X-R↓- sites). For fluorogenic assays, peptide substrates such as Boc-RVRR-AMC or pGlu-RTKR-MCA are well-characterised starting points. Set up reactions in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM CaCl₂, 0.1% Triton X-100 at 37°C, monitoring AMC release at Ex/Em 360/460 nm. A typical starting enzyme concentration is 5–20 nM with substrate at 10–200 µM to bracket Km. Include a heat-inactivated control to confirm signal is enzyme-dependent. Adjust pH between 7.0 and 8.0 to assess pH-rate profiles.

What buffer is PC-4 recombinant supplied in and can I dilute it directly into my assay?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. This storage buffer is compatible with most enzymatic assay systems and can be diluted directly into your reaction mix without dialysis for most applications. If your assay requires low glycerol (<0.5%), dilute the enzyme to working concentration just before use to minimise activity loss from glycerol dilution. Avoid diluting below 0.1 µg/µL in the absence of a carrier protein — add 0.05% BSA to the dilution buffer to prevent surface adsorption losses. Do not introduce reducing agents such as DTT, as these can disrupt critical disulfide bonds.

How should I store recombinant PC-4 and what is the shelf life after thawing?

Store at -20°C in the single-use aliquots provided. Repeated freeze-thaw cycles measurably reduce enzymatic activity; even two additional cycles can result in >30% activity loss for serine endoproteases of this class. Once thawed, keep the aliquot on ice and use within 8 hours. Do not refreeze. For extended working-stock use, prepare further dilutions in assay buffer containing 0.05% BSA and store these at 4°C for no more than 24–48 hours. Shelf life is 12 months from receipt at -20°C when handled correctly. Check the CoA for the activity benchmark specific to your lot.

Can I use recombinant PC-4 as a positive control for Western blot with the matched RP-PC4 antibody?

Yes — this is one of the primary intended uses. The matched rabbit polyclonal antibody RP-PC4 (see /anti-pc-4-rabbit-polyclonal-antibody) was raised and validated against PCSK4 in the same laboratory, ensuring antigen–antibody compatibility. Load 5–20 ng of recombinant PC-4 per lane alongside your cell lysate samples. You should observe a strong band at 90–100 kDa (glycosylated full-length form) and potentially a 70–75 kDa mature-form band. This provides an unambiguous size reference and confirms antibody specificity, particularly useful when running samples from tissues with low endogenous PCSK4 expression.

How much recombinant PC-4 should I load for a Western blot positive control lane?

For most chemiluminescent Western blot setups using RP-PC4 at a 1:500–1:2000 primary antibody dilution, 10–20 ng of recombinant PC-4 per lane produces a robust, non-saturating signal. If you are optimising antibody concentration or comparing sensitivity between detection systems (ECL vs. fluorescent secondary), titrate from 5 ng to 50 ng across replicate lanes. Load the recombinant in Laemmli sample buffer with 5% β-mercaptoethanol and boil for 5 minutes. The denatured, reduced form resolves cleanly at 90–100 kDa and serves as a reliable benchmark for antibody lot-to-lot consistency validation.

How do I determine the IC50 of a PCSK4 inhibitor using this recombinant in a biochemical assay?

Use a fixed enzyme concentration of 5–10 nM PC-4 recombinant and a fluorogenic substrate (e.g., Boc-RVRR-AMC) at or near the apparent Km (~50–100 µM as a starting estimate) to ensure the assay is sensitive to competitive inhibitors. Pre-incubate enzyme with inhibitor for 15–30 minutes at room temperature before substrate addition to allow equilibrium binding. Measure initial velocity (linear phase, first 5–10 minutes) across 8–10 inhibitor concentrations spanning 3 log units. Plot vi/v0 versus [I] and fit to a four-parameter logistic model. Include a PCSK inhibitor reference compound (e.g., dec-RVKR-CMK) as an internal IC50 benchmark across runs.

Validation imagery coming soon

Western blot validation figures for REC-PC4 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →